• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Achieve Life Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    7/6/26 4:06:28 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ACHV alert in real time by email
    8-K
    --12-31false0000949858BC00009498582026-07-022026-07-020000949858dei:OtherAddressMember2026-07-022026-07-02

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): July 2, 2026

    ACHIEVE LIFE SCIENCES, INC.

    (Exact name of Registrant as Specified in Its Charter)

    Delaware

    033-80623

    95-4343413

    (State or Other Jurisdiction

    of Incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification No.)

    22722 29th Drive SE, Suite 100

    Bothell, WA

     

    98021

    1040 West Georgia, Suite 1030

    Vancouver, B.C., Canada

    V6E 4H1

    (Address of Principal Executive Offices)

    (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (604) 210-2217

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading Symbol

    Name of exchange on which registered

    Common Stock, par value $0.001 per share

    ACHV

    The NASDAQ Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

     


    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    On July 6, 2026, following the Annual Meeting of Stockholders (the “Annual Meeting”) of Achieve Life Sciences, Inc. (the “Company”) held on July 2, 2026, the Company filed a certificate of amendment (the “Certificate of Amendment”) to the Company’s third amended certificate of incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to amend the Certificate of Incorporation as contemplated in Proposal 4 (as described in Item 5.07 below). That description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference. The Certificate of Amendment was approved by the Company’s board of directors earlier this year and by the Company’s stockholders at the Annual Meeting.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    The following is a brief description of each matter voted upon at the Annual Meeting and the certified voting results.

    (1)
    Election of nine directors to serve until the Company’s next annual meeting or until the directors’ successors are duly elected and qualified:

     

    For

    Withhold

    Broker
    Non-Votes

    Jeffrey Farrow

    46,282,223

     

     

     

    2,026,985

     

     

     

    20,641,395

    Andrew D. Goldberg

     

     

    48,062,586

     

     

     

    246,622

     

     

     

    20,641,395

     

    Lucian Iancovici

     

     

    48,072,624

     

     

     

    236,584

     

     

     

    20,641,395

     

    Chris Martin

     

     

    48,124,855

     

     

     

    184,353

     

     

     

    20,641,395

     

    Nancy R. Phelan

     

     

    46,287,800

     

     

     

    2,021,408

     

     

     

    20,641,395

     

    Aaron Royston

    48,077,240

     

     

     

    231,968

     

     

     

    20,641,395

    Thomas Sellig

    47,665,074

     

     

     

    644,134

     

     

     

    20,641,395

     

    Richard Stewart

     

     

    47,549,760

     

     

     

    759,448

     

     

     

    20,641,395

     

    Reid Waldman

     

     

    48,085,775

     

     

     

    223,433

     

     

     

    20,641,395

     

    Pursuant to the foregoing votes, the nominees listed above were elected to serve on the Company’s board of directors.

     

    (2)
    Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:

     

    For

    Against

    Abstain

    Broker
    Non-votes

    68,612,907

     

     

     

     

    198,133

     

     

    139,563

     

     

     

    —

     

    Pursuant to the foregoing vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.

     

    (3)
    Approval, by a non-binding advisory vote, of the compensation paid by the Company to its named executive officers:

     


     

     

    For

    Against

    Abstain

    Broker
    Non-votes

    46,351,648

     

     

     

     

    610,744

     

     

    1,346,816

     

     

     

    20,641,395

     

     

    Pursuant to the foregoing non-binding advisory vote, the compensation paid by the Company to its named executive officers was approved.

     

    (4)
    Approval of the Certificate of Amendment to the Certificate of Incorporation to increase the number of the Company's authorized shares of common stock from 150,000,000 shares to 300,000,000 shares:

     

    For

    Against

    Abstain

    Broker
    Non-votes

    64,765,256

     

     

     

     

    3,418,706

     

     

    766,641

     

     

     

    —

     

     

    Pursuant to the foregoing vote, the Certificate of Amendment was approved.

     

     

    Item 9.01

    Financial Statements and Exhibits.

     

     

     

    Exhibit
    Number

    Exhibit Title or Description

     

     

    3.1

    Certificate of Amendment to Third Amended and Restated Certificate of Incorporation, filed July 6, 2026.

     

     

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    ACHIEVE LIFE SCIENCES, INC.

     

    Date: July 6, 2026

     

    /s/ Mark Oki

     

    Mark Oki

    Chief Financial Officer (Principal Financial Officer)

     

     


    Get the next $ACHV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHV

    DatePrice TargetRatingAnalyst
    6/26/2026$20.00Strong Buy
    Raymond James
    4/21/2026$13.00Buy
    Canaccord Genuity
    11/25/2025$19.00Mkt Outperform
    Citizens JMP
    8/21/2025$12.00Buy
    H.C. Wainwright
    11/14/2024$12.00Buy
    Rodman & Renshaw
    9/27/2024$20.00Strong Buy
    Raymond James
    5/10/2023$8.00 → $20.00Buy
    Maxim Group
    10/4/2021$25.00Buy
    Alliance Global Partners
    More analyst ratings

    $ACHV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James resumed coverage on Achieve Life Sciences with a new price target

    Raymond James resumed coverage of Achieve Life Sciences with a rating of Strong Buy and set a new price target of $20.00

    6/26/26 8:18:47 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Canaccord Genuity initiated coverage on Achieve Life Sciences with a new price target

    Canaccord Genuity initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $13.00

    4/21/26 7:30:27 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Citizens JMP initiated coverage on Achieve Life Sciences with a new price target

    Citizens JMP initiated coverage of Achieve Life Sciences with a rating of Mkt Outperform and set a new price target of $19.00

    11/25/25 8:38:19 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Waldman Reid Alexander

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    6/2/26 4:13:36 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Director Farrow Jeffrey S

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    6/2/26 4:12:33 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Waldman Reid Alexander claimed no ownership of stock in the company (SEC Form 3)

    3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    6/2/26 4:11:26 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Achieve Life Sciences Joins Russell 2000® Index

    SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that it has been added to the Russell 2000® Index, effective June 26, 2026, as part of the Russell U.S. Indexes reconstitution. The Company is also a member of the Russell 3000® Index. Approximately $12.2 trillion in assets, as of June 30, 2025, are benchmarked against the Russell U.S. Indexes, making them one of the most widely used benchmarks for institutional investors, ind

    6/29/26 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA

    CRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficiencies Identified SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for cytisinicline. The CRL relates to outstanding manufacturing-related observations from a current Good Manufacturing

    6/22/26 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

    SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Jeffrey Farrow and Reid Waldman, MD have been appointed to its Board of Directors. "Jeffrey and Reid are exactly the kinds of operators you want around a board table when a company is preparing for its first launch," said Lucian Iancovici, MD, incoming Chairman of the Board of Directors of Achieve. "Jeffrey has lived the playbook of taking specialty companies from lat

    6/2/26 8:30:00 AM ET
    $ACHV
    $MANE
    $TARS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ACHV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Oki Mark K bought $28,887 worth of shares (10,000 units at $2.89) (SEC Form 4)

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    3/19/25 4:38:43 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chieve Executive Officer Stewart Richard Alistair bought $28,598 worth of shares (10,000 units at $2.86), increasing direct ownership by 20% to 60,876 units (SEC Form 4)

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    3/19/25 4:32:22 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Stewart Richard Alistair bought $45,850 worth of shares (10,000 units at $4.58), increasing direct ownership by 35% to 38,501 units (SEC Form 4)

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    3/6/24 4:49:23 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    SEC Filings

    View All

    Achieve Life Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

    7/6/26 4:06:28 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form DEF 14A filed by Achieve Life Sciences Inc.

    DEF 14A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

    6/8/26 4:06:22 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update

    8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

    6/2/26 8:51:39 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Leadership Updates

    Live Leadership Updates

    View All

    Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

    Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors  New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone Warrants), Strengthen Achieve's Position to Execute Development and Launch of Cytisinicline, if Approved, as the First New Treatment for Nicotine Dependence in Two Decades SEATTLE and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) today announced it has appointed Andrew D. Goldberg, MD, as Chief Executive Officer and as a member of the Board of Directors, effective following the closing of Achieve's recently announced financing

    4/16/26 8:57:06 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Announces Up to $354 Million Private Placement

    $180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace SEATTLE, Wash. and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities for

    4/16/26 8:53:49 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

    SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) --  Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the appointment of Erik Atkisson as Chief Legal Officer. In his new role, Mr. Atkisson will oversee Achieve's legal strategy, corporate governance, compliance, and risk management. "Erik's extensive legal, regulatory and M&A background in the biopharmaceutical sector provides valuable experience as we advance cytisinicline through regulatory review and prepare for a potential laun

    10/20/25 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Financials

    Live finance-specific insights

    View All

    Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

    Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U.S.-based Manufacturing Transition & Partnership Conference Call Scheduled for 8:30 AM EDT Today, May 12, 2026 SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced financial results for the first quarter of 2026 and provided corporate highlights

    5/12/26 7:00:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026

    SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its first quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q26 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or +1 201-689-7817 (International) and referencing conference ID 13759781. A webcast replay will be avail

    5/5/26 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced financial results for the fourth quarter and full year 2025 and provided updates on the cytisinicline development program, including the announcement of its partnership with Adare Pharma Solutions (Adare). "Achieve is full

    3/24/26 7:00:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Achieve Life Sciences Inc.

    SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

    11/12/24 12:14:09 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Achieve Life Sciences Inc.

    SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

    11/4/24 10:59:37 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Achieve Life Sciences Inc. (Amendment)

    SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

    5/20/24 5:01:27 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care